Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

MannKind Will Acquire Pfizer Insulin Plant

by Ann M. Thayer
March 16, 2009 | A version of this story appeared in Volume 87, Issue 11

MannKind has agreed to purchase Pfizer's insulin factory in Frankfurt, including a quantity of insulin and a license to make it for pulmonary delivery. MannKind will pay $33 million, which may include up to $30 million worth of its stock. Soon to file with the FDA for approval, MannKind has developed the rapid-acting insulin product called Afresa, which is delivered to the lungs as small pH-sensitive particles. Pfizer had built the facility for its failed inhaled insulin product, Exubera. MannKind says the Pfizer site, at which it plans to keep more than half the workforce, complements its Afresa formulation and finishing facility in Danbury, Conn.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.